Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
FOLDAmicus Therapeutics(FOLD) Zacks Investment Research·2024-02-28 22:20

Amicus Therapeutics (FOLD) came out with a quarterly loss of 0.11pershareversustheZacksConsensusEstimateofalossof0.11 per share versus the Zacks Consensus Estimate of a loss of 0.06. This compares to loss of 0.19pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof−83.330.19 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this pharmaceutical company would post a loss of 0.08 per share when it actually produced a loss of $0.07, delivering a surprise of 12.50%. Over the last four quarters, th ...